Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (7733)	11/15/1998 7:48:00 AM
From: WL	Read Replies (1) \| Respond to of 17367

Chicage Tribune Article Yahoo poster noted that XOMA was mentioned in a biotech article from Saturday, 11/14/1998 on the first page of the Business Section. MM recommendation. Here is the link: chicagotribune.com

To: Robert K. who wrote (7733)	11/17/1998 12:55:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Historical interest? Kaye, Scholer, Fierman, Hays & Handler, LLP 425 Park Avenue New York, NY 10022 New York, Washington, DC, Los Angeles, Hong Kong Phone: 212-836-8000 Fax: 212-836-8689 When lawyers and judges complain that jurors fail to grasp legal arguments or scientific concepts, we suggest the problem isn't IQs or educational levels of the jurors. Rather, it's the trial skills of the lawyers who presented the case to them. Long ago, we learned two valuable lessons about juries: 1. Jurors appreciate a good story. Weaving complex scientific or economic information into a compelling story helps the jury in two ways: By humanizing unfamiliar concepts, it holds their attention. And, by providing a frame of reference, it helps them tie together and understand diverse pieces of evidence presented over many weeks of trial. 2. Jurors can't believe what they don't understand. When Xoma Corporation developed something called an "anti-lipid A region monoclonal antibody of the IgM isotype," we demonstrated to the jury - with graphis - how the antibody fastened to microbes like a key in a lock. And we showed how Xoma won the race to invent and patent the first man-made antibody against human sepsis.